Perspective Therapeutics Q3 net loss widens to $26 mln

Perspective Therapeutics

10/11/2025 21:23

Overview

Perspective Therapeutics Q3 net loss widens to $26 mln, EPS at -$0.35

Research and development expenses rose 69% yr/yr in Q3 2025

Cash reserves of $174 mln expected to fund operations into late 2026

Outlook

Company expects funding to support operations into late 2026

Result Drivers

R&D EXPENSES - R&D expenses increased 69% in Q3 2025, driven by higher clinical site activities and personnel costs

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Grant Revenue
$209,000
Q3 EPS
-$0.35
Q3 Net Income
-$25.97 mln
Q3 Net Income from Cont Ops
-$25.97 mln
Q3 Operating Income
-$27.86 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Perspective Therapeutics Inc is $13.50, about 83.7% above its November 7 closing price of $2.20

Press Release: ID:nGNX1R0LP5

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)